FDA approves treatments for irritable bowel syndrome
On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult…




*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.